Training and Resources

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Oncology diagnostics

PD-L1 testing

Pre-analytical phase

Quality IHC testing: pre-analytical phase

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

Analytical phase

Quality IHC testing: analytical phase

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

Quality management

Quality IHC testing: quality monitoring

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

Post-analytical phase

Quality IHC testing: post-analytical phase

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

NSCLC

Prof. John Gosney

Can you test archival NSCLC specimens for PD-L1?

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

Prof. John Gosney

Can testing be performed on ‘cytology’ samples?

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

Prof. John Gosney

Is tumour heterogeneity an issue when assessing PD-L1 status?

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

Digital training module for PD-L1 assessment for non-small cell lung cancer using the tumour proportion score

Digital training module for PD-L1 assessment for non-small cell lung cancer using the tumour proportion score

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

Click here to download the Concordance data for PD-L1 testing for NSCLC

Concordance data for PD-L1 testing for non-small cell lung cancer for KEYTRUDA® (pembrolizumab)

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

HNSCC

Click here to download the Concordance data for PD-L1 testing for HNSCC

Concordance data for PD-L1 testing for head and neck squamous cell carcinoma for KEYTRUDA® (pembrolizumab)

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

UC

Click here to download the Concordance data for PD-L1 testing for UC

Concordance data for PD-L1 testing for urothelial carcinoma for KEYTRUDA® (pembrolizumab)

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

TNBC

Click here to download the Concordance data for PD-L1 testing for TNBC

Concordance data for PD-L1 testing for triple-negative breast cancer for KEYTRUDA^® (pembrolizumab)

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website